Wegovy vs. Mounjaro — How They Differ in Ingredient, Effect, Dosing, and Side Effects
As the weight-loss injectables 'Wegovy' and 'Mounjaro' come up in conversation more and more, many people wonder how the two drugs differ. To get straight to the point: they belong to a similar class, but their active ingredients, mechanisms of action, and approved indications all differ. Above all, these two drugs are not 'weight-loss supplements' but prescription-only specialty medicines that require a doctor's prescription. This article is a neutral reference that summarizes those differences.
Key differences at a glance
- Wegovy: the active ingredient is semaglutide (Novo Nordisk); it acts on a single target, GLP-1; given as a once-weekly subcutaneous injection; in Korea it is approved for the treatment of obesity (launched in 2024).
- Mounjaro: the active ingredient is tirzepatide (Eli Lilly); it acts simultaneously on two hormones, GIP and GLP-1 (dual action); given as a once-weekly subcutaneous injection. In Korea, 'Mounjaro' is indicated for type 2 diabetes, while in the U.S. the same ingredient is approved for obesity under a different name, 'Zepbound.'
- Both drugs work by suppressing appetite and slowing gastric emptying, thereby reducing the amount of food consumed.
- Ozempic and Saxenda, which are in the same Novo Nordisk family, are also GLP-1-class drugs such as semaglutide/liraglutide.
Mechanism of action — why does appetite decrease
Both drugs mimic a hormone called 'GLP-1' that our body secretes when we eat. This hormone acts on the appetite center in the brain to increase the feeling of fullness, and it slows the rate at which food passes through the stomach, so you feel full while eating less. The biggest structural difference from Wegovy is that Mounjaro's tirzepatide is a dual-action drug that additionally acts on another gut hormone called 'GIP.'
How much do the effects differ
In clinical trials, both drugs showed meaningful weight loss, and in some comparisons the dual-action tirzepatide is reported to have produced a larger average reduction. However, this is only a 'clinical average,' and individual variation is very large. Even with the same drug, the effect can be greater or smaller depending on the person, and it is heavily influenced by whether lifestyle measures such as diet and exercise are followed alongside it. No drug 'guarantees' a specific percentage of weight loss, and it is dangerous to treat these as a 'miracle drug.'
Common side effects and safety precautions
- The most common are gastrointestinal disturbances such as nausea, vomiting, diarrhea, and constipation, which usually appear in the early phase when the dose is being raised slowly.
- Rarely, pancreatitis, gallstones, and the like are reported, and if severe abdominal pain persists, immediate medical attention is needed.
- Both drugs carry a boxed warning (thyroid C-cell tumors observed in rodent studies), so they are contraindicated in people with a history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2).
- Those who are pregnant or breastfeeding, or who have severe gastrointestinal disease, among others, must consult a doctor before use.
Oral GLP-1 obesity drugs are still at the 'development/approval stage'
Many people who find injections burdensome are waiting for an 'oral obesity drug.' Orforglipron, under development by Eli Lilly, is an oral GLP-1-class drug that is known to have completed Phase 3 trials and to be at the approval-process stage. However, this is no more than an outlook at the development/approval stage, and the specific domestic launch date, price, brand name, and insurance-coverage status have not been finalized and are subject to change. Information that speaks of a specific product name like 'Pounjaro' as if it has already been launched or finalized is not true; please verify related details directly through the latest official news.
Principles of use you must remember
- They are drugs prescribed at a doctor's discretion when indications (such as BMI) are met — not drugs to self-administer simply because you 'want to lose weight.'
- Use through unofficial channels such as overseas direct purchase, online purchase, or transfer from acquaintances carries a high risk of counterfeit drugs, dosing errors, and side effects.
- When the drug is stopped, appetite returns and weight can rise again (weight rebound), so lifestyle management must go along with it.
- If prescribed without insurance coverage, the cost can be high, and the price and coverage status differ depending on the time and indication.
Even within the same GLP-1 class, the active ingredient, indications, and mechanism of action differ, so which drug is right for you should be decided through medical consultation, not an online search.